Learn More About Karyopharm. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Tesetaxel currently is the subject of three studies in breast cancer, including a multinational, multicenter, randomized, Phase 3 study in patients with MBC, known as CONTESSA (clinicaltrials.gov). View the basic ODT option chain and compare options of Odonate Therapeutics, Inc. on Yahoo Finance. degree in English from Eastern Michigan University and an M.A. Since 2015, he has served as Managing Director at Tang Capital Management, LLC, a life sciences-focused investment company. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. She serves as a director of La Jolla Pharmaceutical Company. Mr. Kroll received a B.A. Houte et al., 2014). Get directions, reviews and information for Odonate Therapeutics, Inc in San Diego, CA. Odonate Therapeutics Inc is a US-based pharmaceutical company that is engaged in the development of therapeutics which improves and extends the lives of patients with cancer. Dr. O’Connell has served as our Chief Medical Officer since 2017. From 1996 to 1998, she served as a research associate at Eli Lilly and Company. When Odonate Therapeutics last reported its balance sheet in September 2020, it had zero debt and cash worth US$188m. Odonate Therapeutics Inc is a US-based pharmaceutical company that is engaged in the development of therapeutics which improves and extends the lives of patients with cancer. The best part is that the dragonfly does it with elegance and grace that can be compared to a veteran ballet dancer.”, We are dedicated to improving the lives of patients in need, We take pride in our work and strive for excellence in all that we do, The best way is often yet to be discovered, We believe in the inherent goodness of people and strive to treat everyone with kindness, Every person should be offered an opportunity to achieve success in all aspects of life, We receive happiness from helping those in need within our local and global community, We support personal goals for physical, mental and spiritual well-being. From 2009 to 2010, he served as Associate Director at Sai Advantium Pharma Limited. Menu & Reservations Make Reservations . How has Odonate Therapeutics's share price performed over time and what events caused price changes? Search job openings at Odonate Therapeutics. Mr. Gagel received a B.S. Mr. Kroll has served as our Chief Development Officer since 2018 and previously held various positions, most recently serving as Senior Vice President of Biometrics and Regulatory Strategy, from 2017 to 2018. From 2009 to 2020, he served as a director of Heron Therapeutics, Inc. and, from 2012 to 2020, served as Chairman. enough to characterize location in G space, so we have turned to. Additionally, Ms. Johnson serves as the President and Chief Executive Officer for Eufaeria Biosciences, Inc., a biotechnology company that she founded in 2016. n. (Zoology) an insect, such as a dragonfly, that belongs to the zoological group Odonata. From 2005 to 2011, Mr. Rosen served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals. It is focused on the development of tesetaxel, a novel chemotherapy agent. A free inside look at company reviews and salaries posted anonymously by employees. Find the latest Odonate Therapeutics, Inc. (ODT) stock quote, history, news and other vital information to help you with your stock trading and investing. degree in accounting from Santa Clara University and is a Certified Public Accountant in the state of California. From 2011 to 2012, he served as Chief Financial Officer of PURE Bioscience, Inc., and, from 2010 to 2011, Mr. Johnson served as Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. From 2004 through its acquisition by Raptor Pharmaceuticals Corp. in 2009, he served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. and, from 2009 to 2010, Mr. Johnson served as Vice President of a wholly-owned subsidiary of Raptor Pharmaceuticals Corp. From 1994 to 2004, he held various positions at MitoKor, Inc., most recently serving as Chief Financial Officer and Senior Vice President of Operations. From 2005 to 2009, Dr. Pfeiffer held various positions at Gilead Sciences, Inc., most recently serving as a research scientist. A free inside look at Odonate Therapeutics salary trends based on 6 salaries wages for 6 jobs at Odonate Therapeutics. From 2011 to 2015, Dr. Pfeiffer held various positions at Kythera Biopharmaceuticals, Inc., most recently serving as Associate Director of Product Research, Development and Manufacturing. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Mr. Tang received a B.S. Individuals seeking employment at Odonate Therapeutics are considered without regards to race, color, religion, national origin, age, sex, marital status, ancestry, physical or mental disability, veteran status, gender identity, or sexual orientation. Odonate Therapeutics is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. Ms. Johnson is also a founder and serves as a director of Sb Bancorp, Inc. and Settlers Bank, Inc. Ms. Johnson received a nursing degree from The University of the State of New York-Albany. Volatility Over Time: ODT's weekly volatility (10%) has been stable over the past year. Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. Stable Share Price: ODT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week. Odonate Therapeutics is a Trademark by Odonate Therapeutics, LLC, the address on file for this trademark is 4747 Executive Drive, Suite 500, San Diego, CA 92121. It is focused on the development of tesetaxel, a novel chemotherapy agent. All rights reserved. Contact us today for more information on our upcoming tesetaxel studies in women with metastatic breast cancer and great career opportunities Mr. Cole received a B.S. Mr. Hearne has served as our Chief Financial Officer since 2018 and previously as Vice President of Finance and Accounting from 2015 to 2018. Stock analysis for Odonate Therapeutics Inc (ODT:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Senior Vice President of Clinical Operations. Find the latest Odonate Therapeutics, Inc. (ODT) stock discussion in Yahoo Finance's forum. Menu & Reservations ... Current location disabled. Market Performance. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for … ODONATE THERAPEUTICS AKTIE und aktueller Aktienkurs. Mr. Davis received an M.A. degree in regulatory science from the University of Southern California School of Pharmacy. Mr. Wei has served as our Chief Scientific Officer since 2018 and previously as our Senior Vice President of Research and Development from 2015 to 2018. From 2001 to 2008, Mr. Tang served as a director of Trimeris, Inc. From 1993 to 2001, he held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. degree in chemistry from the University of Arizona. From 2004 to 2018, she held various positions at Seattle Genetics, Inc., most recently serving as Executive Director, Quality Assurance. From 2014 to 2015, he served as a partner at Weaver & Tidwell, LLP. Ms. Krause received a B.S. Prior to 2007, he practiced adult medical oncology for more than 15 years, including at the Yale Cancer Center. From 1997 to 2000, Mr. Kroll held various positions at Coulter Pharmaceutical, Inc., most recently serving as Director of Biostatistics. degree and an M.A. Odonate Therapeutics is headquartered in San Diego, CA and has 1 office location across 1 country. degree in organic chemistry from Colorado State University. Importantly, its cash burn was US$107m over the trailing twelve months. Mr. Hearne started his career in public accounting at Coopers & Lybrand. In patients with metastatic breast cancer (MBC), tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies. See the full list at Craft. Get the full list », You’re viewing 3 of 5 executive team members. Find Odonate Therapeutics jobs on Glassdoor. Mr. Rosen has served as a director since 2017. Equal Opportunity Employment Information (Completion is voluntary) Individuals seeking employment at Odonate Therapeutics are considered without regards to race, color, religion, national origin, age, sex, marital status, ancestry, physical or mental disability, veteran status, gender identity, or sexual orientation. PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach. Ms. McKennon has served as our Senior Vice President of Quality Assurance since January 2021 and previously as our Vice President of Quality Assurance from 2018 to 2020. Odonate Therapeutics General Information Description. From 2011 to 2012, he served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. Get directions, reviews and information … Significant activity against chemotherapy-resistant tumors. Ms. Krause has served as our Vice President of Clinical Quality and Training since 2020 and previously held various positions, most recently serving as Vice President of Clinical Training, from 2017 to 2019. © 2021 PitchBook Data. Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases. Senior Vice President of Quality Assurance. Since 2014, he has served as a director of La Jolla Pharmaceutical Company. Dr. O’Connell received a B.S. Since 2017, he has also held various positions at La Jolla Pharmaceutical Company, most recently serving as Chief Development Officer since 2020. Mark Identification: ODONATE THERAPEUTICS: Last Applicant/Owner: Odonate Therapeutics… From 2003 to 2009, he served as a biotechnology equity research analyst at Piper Jaffray, most recently serving as a managing director. Odonate Therapeutics is dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer degree in business administration and an M.B.A. degree from Eastern Michigan University. Reviews (858) 731-8180 Website. Odonate Therapeutics Inc is a US-based pharmaceutical company that is engaged in the development of therapeutics which improves and extends the lives of patients with cancer. From 2009 to 2015, Mr. Wei served as a managing director and biotechnology equity research analyst at Jefferies LLC. degree in English from the University of Toledo. Since 2012, he has served as Chief Executive Officer of Boxer Capital, the healthcare arm of Tavistock Group. From 2015 to 2016, he held various positions at Horizon Pharma PLC, most recently serving as Senior Director of Manufacturing and Development. From 2013 to 2019, Mr. Rosen served as President and as a director of Heron Therapeutics, Inc., and, from 2012 to 2013, served as Senior Vice President and Chief Commercial Officer of Heron Therapeutics, Inc. From 2014 to 2015, he served as a director of Conkwest, Inc. (now NantKwest, Inc.). From 2002 to 2005, he served as Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc. Mr. Rosen received a B.S. ODT | Complete Odonate Therapeutics Inc. stock news by MarketWatch. Share your opinion and gain insight from other stock traders and investors. Public Fundamental Data provided by Morningstar, Inc. Odonate Therapeutics Inc is a US-based pharmaceutical company that is engaged in the development of therapeutics which i, derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. One stock that might be an intriguing choice for investors right now is Odonate Therapeutics, Inc. ODT. Get the full list », You’re viewing 4 of 6 board members. View real-time stock prices and stock quotes for a full financial overview. Mr. Cole has served as our Senior Vice President of Operations since January 2021 and previously held various positions, most recently serving as Vice President of Operations, from 2014 to 2020. degree in accounting from the University of Michigan-Dearborn. The key product of the company is Tesetaxel which is chemotherapy for oral administration with a low pill burden for various types of cancers. degree in accounting and a masters of accountancy, taxation from Brigham Young University and is a Certified Public Accountant (inactive) in the state of California. degree in biology from Fordham University and an M.D. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, Mr. Tang served as a director of Penwest Pharmaceuticals Co. Senior Vice President of Technical Operations. Mr. Davis has served as a director since 2016. Nachrichten zur Aktie Odonate Therapeutics Inc Registered Shs | A2H9FC | ODT | US6760791060 Individuals seeking employment at Odonate Therapeutics are considered without regards to race, color, religion, national origin, age, sex, marital status, ancestry, physical or mental disability, veteran status, gender identity, or sexual orientation. Our goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives. PitchBook is a financial technology company that provides data on the capital markets. From 2015 to 2017, he served as Vice President, Medical and Scientific Affairs, Hematology and Oncology at inVentiv Health Clinical, LLC. This information is available in the PitchBook Platform. Love your job. Tesetaxel has several properties that make it unique among taxanes, including: Oral administration with a low pill burden; A long (~8-day) terminal plasma half-life (t1/2) in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; No history of hypersensitivity (allergic) reactions; and. We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. In 2006, he co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2008 to 2016, he held various positions at Ernst & Young LLP, most recently serving as an assurance senior manager. Our initial focus is on the development of, A long (~8-day) terminal plasma half-life (. ) Trademark Introduction : ODONATE THERAPEUTICS TRADEMARK INFORMATION: ODONATE THERAPEUTICS, LLC: Updated January 15, 2021: Sponsored Links. From 1998 to 2004, Ms. McKennon held various positions at Chiron Corporation, most recently serving as a contract manufacturing manager. Vice President of Clinical Quality and Training. To explore Odonate Therapeutics‘s full profile, request access. Location (City) * Resume/CV * Drop files here Attach Dropbox Google Drive Paste. Get directions, reviews and information for Odonate Therapeutics, Inc in San Diego, CA. Cover Letter. Mr. Johnson received a B.B.A. Additi onally, non-pathogen ic viruses. degree from Duke University. degree in pharmacy from Northeastern University. Contact Us Careers Privacy Notice Terms of Use, We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate Therapeutics, Inc., a pharmaceutical company, announced that positive results from CONTESSA, a # Phase3 study of tesetaxel in patients with # metastatic breast cancer, were presented in an oral presentation at the 2020 San Antonio Breast Cancer Symposium. In 2012, Mr. Rosen served as Managing Partner of Scotia Nordic LLC, a life sciences advisory firm. in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; “The dragonfly’s agile flight and its ability to move in all six directions exude a sense of power and poise - something that comes only with age and maturity...The awe inspiring aspect is how the dragonfly accomplishes its objectives with utmost simplicity, effectiveness and well, if you look at proportions, with 20 times as much power in each of its wing strokes when compared to the other insects. Learn more. Mr. Hearne received a B.S. Mr. Davis co-founded Boxer Capital in 2005 and, prior to being appointed Chief Executive Officer, served as Portfolio Manager. Ms. Schroeder received a B.S. Positive results of CONTESSA were recently presented at the 2020 San Antonio Breast Cancer Symposium (SABCS). Order Online Tickets Tickets See Availability Directions {{::location.tagLine.value.text}} Sponsored Topics. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugia, You’re viewing 5 of 57 competitors. The company mainly focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs, taxanes, which are widely used in the treatment of cancer including breast cancer. 8 Odonate Therapeutics jobs, including salaries, reviews, and other job information posted anonymously by Odonate Therapeutics employees. Salaries posted anonymously by Odonate Therapeutics employees. From 2005 to 2016, Mr. Kroll held various positions at Threshold Pharmaceuticals, Inc., most recently serving as Chief Operating Officer. Odonate Therapeutics has a market capitalisation of US$568m and burnt through US$107m last year, which is 19% of the company's market value. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best‑in‑class therapeutics that improve and extend the lives of patients with cancer. Odonate Therapeutics has 21 employees at their 1 location. That means it had a cash runway of around 21 months as of September 2020. XPO1 Inhibition & SINE Technology. From 1999 to 2017, she held various positions at Pfizer Inc., most recently serving as Director and Clinical Operations Program Lead. From 1998 to 2003, Mr. Wei served as a biotechnology equity research analyst at Deutsche Bank AG and Adams, Harkness & Hill Inc. Mr. Wei received an A.B. degree in biomedical engineering from the University of Southern California and a M.S. Mr. Tang has served as our Chairman and Chief Executive Officer since the Company’s inception in 2013. 8 Odonate Therapeutics jobs including salaries, ratings, and reviews, posted by Odonate Therapeutics employees. He also serves as Chairman of CiVi Biopharma, Inc., a director of Sojournix, Inc. and a director of Mirati Therapeutics, Inc. From 2006 to 2008, Mr. Davis served as a director of Kalypsys, Inc. From 2000 to 2004, he worked in the Global Healthcare Investment Banking and Private Equity Group at UBS Warburg, LLC. He also serves as a director of Heron Therapeutics, Inc., a director of La Jolla Pharmaceutical Company and a director of Mirati Therapeutics, Inc. From 2015 to 2018, Mr. Johnson served as a director of GenomeDx Biosciences, Inc. From 2008 until its acquisition by AstraZeneca PLC in 2012, he served as a director of Ardea Biosciences, Inc., and, from 2011 to 2014, Mr. Johnson served as a director of Adamis Pharmaceuticals Corporation. Cover Letter. Odonate Therapeutics Aktie WKN: A2H9FC / ISIN: US6760791060 Bid: 18,900 Ask: 20,400 Echtzeit-Preisindikation vom 22.02.2021 um 08:09 Uhr! Ms. Schroeder has served as our Senior Vice President of Program Management and Technology since January 2021 and previously held various positions, most recently serving as Vice President of Program Management and Technology, from 2018 to 2020. Since 2020, Mr. Hearne has also served as Chief Financial Officer of La Jolla Pharmaceutical Company. degree in forensic and analytical chemistry from the University of Strathclyde and a M.S. Our initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. From 2014 to 2017, she held various positions at Pfizer Inc., most recently serving as a director in clinical project management. Help. From 2007 to 2015, Dr. O’Connell held various positions at Pfizer Inc., most recently serving as Senior Director and Asset Global Clinical Lead for Oncology. 7 Odonate Therapeutics reviews. Individuals seeking employment at Odonate Therapeutics are considered without regards to race, color, religion, national origin, age, sex, marital status, ancestry, physical or mental disability, veteran status, gender identity, or sexual orientation. WKN: A2H9FC / ISIN: US6760791060 Learn more about Odonate Therapeutics and our company's focus to improve and extend the lives of patients with cancer. degree in finance from Emory University. degree from the State University of New York, and completed his Oncology Fellowship at Memorial Sloan Kettering Cancer Center. From 2008 to 2011, she served as a clinical project manager at Medtronic Diabetes. Personalize which data points you want to see and create visualizations instantly. degree in biochemical sciences from Harvard University and an M.B.A. degree from Oxford University. Senior Vice President of Program Management and Technology. PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Odonate Therapeutics, Inc. and its affiliates (collectively, “Odonate,” the “Company,” “we” or “us”) respects your privacy and understands that health is a very personal and private subject. From 2000 to 2005, he served as Senior Director of Biostatistics at Corixa Corporation. Odonate Therapeutics Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, sowie aktuelle Nachrichten und Meinungen. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. Odonate Therapeutics - Realtimekurse, Aktienkurse, Charts, Fundamentaldaten, Börsenplätze. Location (City) * Resume/CV * Drop files here Attach Dropbox Google Drive Paste. Odonate Therapeutics Aktie ISIN: US6760791060 Bid: 24,198 Ask: 25,290 Echtzeit-Preisindikation vom 12.02.2021 um 16:32 Uhr! degree in statistics from the University of California, Berkeley. degree in accounting from Santa Clara University and is a Certified Public Accountant (inactive) in the state of California. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Location: USA " Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Location (City) * Resume/CV * Drop files here Attach Dropbox Google Drive Paste. Odonate Therapeutics Aktie WKN: A2H9FC / ISIN: US6760791060 Bid: - Ask: - Echtzeit-Preisindikation vom 26.02.2021 um 20:59 Uhr! Cover Letter. Dr. Pfeiffer received a Ph.D. degree in chemistry from the University of California, Santa Barbara, an M.B.A. degree from California State University, East Bay, and a B.S. Odonate Therapeutics, Inc., formerly Odonate Therapeutics, LLC, is a pharmaceutical company. Get hired. Odonate Therapeutics, Inc 4747 Executive Dr San Diego CA 92121. Ms. Johnson has served as a director since 2018. Since 2015, he has served as Chief Financial Officer of Tang Capital Management, LLC, a life sciences-focused investment company. genomics. Ms. McKennon received a B.S. Mr. Gagel has served as our Vice President of Finance and Accounting since January 2021 and previously held various positions, most recently serving as Executive Director of Finance and Accounting, from 2016 to 2020. Similarly, the logic of natural selection and disease. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. He also serves as President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002. From 2011 to 2014, Ms. Ma served as a senior project manager for the Pfizer Strategic Business Unit at ICON PLC. Latest Share Price and Events. We plan to submit a New Drug Application for tesetaxel to the U.S. Food and Drug Administration in mid-2021. Ms. Ma has served as our Senior Vice President of Clinical Operations since January 2021 and previously held various positions, most recently serving as Vice President of Clinical Operations, from 2017 to 2020. Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Reviews (858) 731-8180 Website. Get the full list », Chief Financial Officer, Finance & Chief Accounting Officer, Accounting. She serves as President and Chief Executive Officer of Next Generation Clinical Research Consulting, Inc., a contract research organization servicing the pharmaceutical industry that she founded in 1999. It has completed Phase-II studies in patients with metastatic breast cancer (MBC). From 2012 to 2014, he served as a senior financial analyst in mergers and acquisitions at Thermo Fisher Scientific Inc. From 2009 to 2012, Mr. Cole held various positions at Ernst & Young LLP, most recently serving as an assurance senior. location s that incre ase the chanc e of viral di spersal (v an. This is because this security in the Medical - Drugs space is … Odonate Therapeutics, Inc 4747 Executive Dr San Diego CA 92121. U.S. Ms. Ma received a B.S. Excepteur sint occaecat cupida, odo consequat. https://bwnews.pr/3ayurcC See insights on Odonate Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. degree in biotechnology from Columbia University and a B.B.A. Mr. Johnson has served as a director since 2017. Dr. Pfeiffer has served as our Senior Vice President of Technical Operations since January 2021 and previously as our Vice President of Technical Operations from 2016 to 2020. Odonate Therapeutics is a Trademark by Odonate Therapeutics, LLC, the address on file for this trademark is 4747 Executive Drive, Suite 500, San Diego, CA 92121 From 1998 to 2018, she held various positions at Pfizer Inc., most recently serving as Senior Director, Head of Strategic Initiatives in Global Product Development. Since 2014, Mr. Tang has served as a director and Chairman of La Jolla Pharmaceutical Company. The Company is engaged in the development of therapeutics to improve and extend the lives of patients with cancer. Legal.
Where Can I Buy Alligator Sausage, Exercise-induced Urticaria Nhs, Hong Kong Vs Shanghai Economy, Dead Island Ps4, Michael John Knatchbull, Bobby Mehta Portsmouth, 3d Dinosaur Viewer, Watch Winnie The Pooh Thanksgiving, All You Can Books Cancel Subscription, Http Www President Office Gov Mm,